2024-03-29T15:35:19Z
https://nagoya.repo.nii.ac.jp/oai
oai:nagoya.repo.nii.ac.jp:00028368
2023-01-16T04:20:58Z
499:500:501
Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan
Kawashima, Nozomu
92724
Iida, Minako
92725
Suzuki, Ritsuro
92726
Fukuda, Takahiro
92727
Atsuta, Yoshiko
92728
Hashii, Yoshiko
92729
Inoue, Masami
92730
Kobayashi, Masao
92731
Yabe, Hiromasa
92732
Okada, Keiko
92733
Adachi, Souichi
92734
Yuza, Yuki
92735
Kawa, Keisei
92736
Kato, Koji
92737
Mycophenolate mofetil
Graft-versus-host disease
Prophylaxis
Treatment
Pediatric
We investigated the safety and efficacy of mycophenolate mofetil (MMF) in the prevention and treatment of graft-versus-host disease (GVHD) using a nationwide retrospective survey in Japanese children undergoing hematopoietic stem cell transplantation (HSCT). Overall, 141 children undergoing allogeneic HSCT for hematological malignancy (n = 84), non-malignancy (n = 52), and solid tumors (n = 5) were administered MMF orally (median 8 years; range 0–15 years; 89 males and 52 females) during 1995–2011. Donors were primarily unrelated and mismatched related. In the GVHD prophylaxis group, 29% and 8.6% of patients developed grade II–IV and III–IV GVHD, respectively. Of the 32 evaluable patients, 16% developed chronic [limited (n = 4) and extensive (n = 1)] GVHD. In the acute GVHD treatment group, 61% had decreased grade. In the chronic GVHD treatment group, 36% had improved symptoms. Combined immunosuppressant was reduced or discontinued in 61% patients. Major adverse events (AEs) were neutropenia (4.3%), infection (3.5%), thrombocytopenia (2.1%), myelosuppression (2.1%), and diarrhea (1.4%). MMF dosage was reduced in two children due to grade ≥ 3 AEs; two children died from infection. MMF thus may be well tolerated in children, and may be an effective option for prophylaxis and treatment of acute and chronic GVHD.
ファイル公開:2020/04/01
journal article
Elsevier
2019-04
application/pdf
application/pdf
International Journal of Hematology
4
109
491
498
0925-5710
https://nagoya.repo.nii.ac.jp/record/28368/files/MMF_for_Pediatric_HSCT_MS9_IJH1.pdf
https://nagoya.repo.nii.ac.jp/record/28368/files/IJH_PedMMF_Suppl.pdf
eng
https://doi.org/10.1007/s12185-019-02601-5
“This is a post-peer-review, pre-copyedit version of an article published in [International Journal of Hematology]. The final authenticated version is available online at: http://dx.doi.org/10.1007/s12185-019-02601-5”.